Tegafur-induced acral hyperpigmentation

Vera Teixeira; Ricardo Vieira; Américo Figueiredo

doi:10.4081/dr.2011.e30

Tegafur-induced acral hyperpigmentation

https://doi.org/10.4081/dr.2011.e30

PDF HTML

Vol. 3 No. 2 (2011)

Submitted: 23 August 2011
Accepted: 24 August 2011

Published: 30 September 2011

tegafur, 5-fluorouracil, acral hyperpigmentation

Abstract Views: 1828

PDF: 792
HTML: 251

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Vera Teixeira
verafmup@hotmail.com
University Coimbra Hospital, Portugal.
Ricardo Vieira Department of Dermatology, Coimbra University Hospital, Portugal.
Américo Figueiredo Department of Dermatology, Coimbra University Hospital, Portugal.

Tegafur is a prodrug of 5-fluorouracil (5-FU) with a similar spectrum of antitumor activity. It is used in the treatment of advanced gastrointestinal neoplasms. Over 5-FU, tegafur has the advantage of oral administration and less hematologic toxicity. Gastrointestinal toxicity is its main dose-limiting factor. The cutaneous adverse effects of tegafur include mucositis, photosensitivity, diffuse or nail-restricted hyperpigmentation, palmoplantar erythrodysesthesia syndrome, palmoplantar keratoderma, sclerodactyly and Raynaud phenomenon. We report here the case of a patient who developed acral hyperpigmentation during treatment with tegafur.

Vera Teixeira, University Coimbra Hospital

Department of Dermatology

Supporting Agencies

none

Teixeira, V., Vieira, R., & Figueiredo, A. (2011). Tegafur-induced acral hyperpigmentation. Dermatology Reports, 3(2), e30. https://doi.org/10.4081/dr.2011.e30